系统性红斑狼疮患者血小板参数及血小板反应蛋白1水平与疾病活动度的关系

doi:10.3969/j.issn.1671-7171.2024.02.028

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1270 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨系统性红斑狼疮(SLE)患者血小板(PLT)相关参数及PLT反应蛋白1(TSP-1)水平与疾病活动度的关系。【方法】本院收治的83例SLE患者为观察组,另选取同期体检的62例健康志愿者为对照组。比较两组一般资料、生化指标、PLT相关参数及TSP-1水平,采用Logistic多因素回归分析影响SLE患者疾病活动度的相关因素,采用受试者工作特征(ROC)曲线分析PLT参数及TSP-1评估SLE患者疾病活动度的价值。【结果】观察组PLT计数、PLT压积、大PLT百分率均低于对照组(P<0.05),观察组PLT平均容积(MPV)、PLT体积分布宽度(PDW)、TSP-1水平均高于对照组(P<0.05)。Logistic多因素回归分析显示,IgG、MPV、C3、C4、PLT、TSP-1水平是影响SLE患者疾病活动度的相关因素(P<0.05)。ROC曲线分析显示,MPV、PLT、TSP-1及三者联合评估SLE患者疾病活动度的灵敏度分别为72.41%、75.86%、68.97%、79.31%,特异度分别为70.37%、79.63%、77.78%、83.33%,曲线下面积(AUC)分别为0.723、0.751、0.739、0.892。【结论】PLT参数中的MPV、PLT及TSP-1与SLE患者疾病活动度有关,其联合评估SLE患者疾病活动度的效能良好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	朱桂芝
	王峰
	曲燕
	倪萍

关键词 ：红斑狼疮,系统性, 血小板计数, 血小板生成素

Abstract：【Objective】To explore the relationship between platelet (PLT) related parameters, PLT reactive protein 1 (TSP-1) levels, and disease activity in patients with systemic lupus erythematosus (SLE). 【Methods】A total of 83 SLE patients admitted to our hospital were selected as the observation group, and 62 healthy individuals who underwent physical examinations during the same period were selected as the control group. Two groups of general information, biochemical indicators, PLT related parameters, and TSP-1 levels were compared; Logistic multiple regression analysis was used to identify the factors influencing disease activity in SLE patients, and receiver operating characteristic (ROC) curve analysis was used to evaluate the value of PLT parameters and TSP-1 in evaluating disease activity in SLE patients. 【Results】 The PLT count, PLT volume, and percentage of large PLT in the observation group were all lower than those in the control group (P<0.05). The average PLT volume (MPV), PLT volume distribution width (PDW), and TSP-1 level in the observation group were higher than those in the control group (P<0.05). Logistic multiple regression analysis showed that IgG, MPV, C3, C4, PLT, and TSP-1 levels were related factors affecting disease activity in SLE patients (P<0.05). ROC curve analysis showed that the sensitivity of MPV, PLT, TSP-1, and their combined evaluation for disease activity in SLE patients were 72.41%, 75.86%, 68.97%, and 79.31%, respectively. The specificity was 70.37%, 79.63%, 77.78%, and 83.33%, respectively. The area under the curve (AUC) was 0.723, 0.751, 0.739, and 0.892, respectively.【Conclusion】 MPV, PLT, and TSP-1 in PLT parameters are related to disease activity in SLE patients, and their combined evaluation of disease activity in SLE patients has good efficacy as evaluation indicators.

Key words： Lupus Erythematosus,Systemic Platelet Count Thrombopoietin

收稿日期: 2023-06-26

中图分类号:

R593.241

通讯作者: *E-mail:niping7201@sina.com

引用本文:

朱桂芝, 王峰, 曲燕, 倪萍. 系统性红斑狼疮患者血小板参数及血小板反应蛋白1水平与疾病活动度的关系[J]. 医学临床研究, 2024, 41(2): 258-261.
ZHU Guizhi, WANG Feng, QU Yan, et al. The Relationship between Platelet Parameters, Platelet Reactive Protein 1 Levels, and Disease Activity in Patients with Systemic Lupus Erythematosus. JOURNAL OF CLINICAL RESEARCH, 2024, 41(2): 258-261.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.02.028 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I2/258

[1] LIPSKY P E, VOLLENHOVEN R V, DÖRNER T, et al. Biological impact of iberdomide in patients with active systemic lupus erythematosus[J].Ann Rheum Dis,2022, 81(8):1136-1142.
[2] CHATHAM W W, FURIE R, SAXENA A, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase Ⅱ open-label extension study[J].Arthritis Rheumatol,2021, 73(5):816-825.
[3] ANTONIAK S, MACKMAN N. Platelets and viruses[J].Platelets,2021, 32(3):325-330.
[4] KALE A, ROGERS N M, GHIMIRE K. Thrombospondin-1 CD47 signalling: from mechanisms to medicine[J].Int J Mol Sci,2021, 22(8):4062-4065.
[5] 伍伟, 何东初. 系统性红斑狼疮患者血清血小板反应蛋白1水平与病情严重程度的关系[J].中国医药导报, 2020, 17(2):93-96.
[6] 中华医学会风湿病学分会. 系统性红斑狼疮诊断及治疗指南[J].中华风湿病学杂志, 2010, 14(5):342-346.
[7] DI BARTOLOMEO S, ALUNNO A, CARUBBI F. Respiratory manifestations in systemic lupus erythematosus[J].Pharmaceuticals (Basel),2021, 14(3):276-281.
[8] TZENG H T, CHYUAN I T. Immunometabolism in systemic lupus erythematosus: Relevant pathogenetic mechanisms and potential clinical applications[J].J Formos Med Assoc,2021, 120(9):1667-1675.
[9] ALLEN M E, RUS V, SZETO G L. Leveraging heterogeneity in systemic lupus erythematosus for new therapies[J].Trends Mol Med,2021, 27(2):152-171.
[10] MARISCAL A, ZAMORA C, MAGALLARES B, et al. Phenotypic and functional consequences of PLT binding to monocytes and its association with clinical features in SLE[J].Int J Mol Sci,2021, 22(9):4719-4723.
[11] ROWETH H G, BATTINELLI E M. Lessons to learn from tumor-educated platelets[J].Blood,2021, 137(23):3174-3180.
[12] WIRESTAM L, GULLSTRAND B, JERN A, et al. Low Intra-individual variation in mean platelet volume over time in systemic lupus erythematosus[J].Front Med (Lausanne),2021, 20(4):150-158.
[13] NAZY I, JEVTIC S D, MOORE J C, et al. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia[J].J Thromb Haemost,2021, 19(5):1342-1347.
[14] KAUR S, BRONSON S M, PAL-NATH D, et al. Functions of thrombospondin-1 in the tumor microenvironment[J].Int J Mol Sci,2021, 22(9):4570-4576.